More women to benefit from breast cancer risk predictor

Islacare is working with academic and clinical partners to improve access to a ‘gold standard’ assessment of future breast cancer risk.

The pioneering CanRisk web-based programme has been developed by the Centre for Cancer Genetic Epidemiology at the University of Cambridge. It is funded by Cancer Research UK as part of a wide-ranging research project. The assessment uses information about genetics, epidemiology, lifestyle and hormone profile to estimate a woman’s risk of breast cancer.

The sophisticated predictive calculation requires broad information from patients, which can be difficult to obtain at a busy hospital clinic. Isla’s user-friendly platform allows the patient to provide the relevant information conveniently and securely prior to review in clinic.

Many more women in the East of England can expect to benefit from the pioneering CanRisk assessment following its integration with Isla’s visual care record. The lead clinician for this research partnership is Mr Alexander Leeper, Consultant Oncoplastic Breast Surgeon at James Paget University Hospital NHS Foundation Trust.

CanRisk is acknowledged as a gold standard in calculating a patient’s future risk of breast cancer. We’re using the Isla technology to make CanRisk more accessible to clinicians and to improve how we identify and grade patients’ future risk. – Mr Leeper

“By collecting information from patients before we see them physically, we hope to improve efficiency in our busy clinics. And patients will greatly benefit from having the best possible understanding of their future risk of developing breast cancer and what they can do to reduce their risk.”

CanRisk uses sophisticated risk prediction modelling to help clinicians in primary, secondary and tertiary healthcare make judgements and provide advice around risk reduction through personalised screening, preventive medicine, lifestyle modification and environment.

“Our vision is to use the benefits of CanRisk for all patients who attend breast clinic concerned about their breast health,” said Mr Leeper. “The dynamic team at Isla is helping us turn this vision into reality. Isla continues to build a strong record of remotely collecting relevant data from patients through their straightforward and user-friendly platform.”

Isla is growing rapidly in the health tech sector and has developed the visual component of the medical record. Pete Hansell, co-founder, said Isla is delighted to be working with academic and clinical partners in another ground-breaking project.

“At Isla, we’re passionate most of all about getting great technology to clinicians and integrating it seamlessly into their clinical practices so they can improve patients’ experiences and outcomes,” he said.

“We’re really excited to be working in partnership with leading clinicians, The University of Cambridge research community and the broader innovation teams in the East of England to integrate the CanRisk assessment tool into the Isla visual record.”

“This will allow patients to submit information seamlessly and conveniently. Clinicians will then get an immediate response from the sophisticated modelling provided by CanRisk, which will support them in delivering high-quality care and advice to their patients in the clinic. We’re pleased to be making it easier for clinicians to use this assessment on a larger scale.”

See more about how Isla works.